{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10","value":"17.2"},{"groupId":"OG002","spread":"5.65","value":"15.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Cycle 1, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.88","value":"16.8"},{"groupId":"OG002","spread":"8.47","value":"24.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Cycle 3, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.6","value":"29.1"},{"groupId":"OG002","spread":"5.66","value":"20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Cycle 1, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.17","value":"24.2"},{"groupId":"OG002","spread":"15.7","value":"25.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"title":"Cycle 3, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.77","value":"17.8"},{"groupId":"OG002","spread":"7.3","value":"18.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 1, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.02","value":"18.4"},{"groupId":"OG002","spread":"5.05","value":"24.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 3, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.98","value":"19.1"},{"groupId":"OG002","spread":"7.49","value":"25.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Cycle 1, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.5","value":"25.2"},{"groupId":"OG002","spread":"8.11","value":"17.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Cycle 3, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.33","value":"18.8"},{"groupId":"OG001","spread":"7.43","value":"21.3"},{"groupId":"OG002","spread":"6.24","value":"19.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"Cycle 1, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.1","value":"23.9"},{"groupId":"OG001","spread":"0.591","value":"22.2"},{"groupId":"OG002","spread":"5.64","value":"23.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"Cycle 3, TNBC patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"61"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Elimination half-life (T1/2) values were calculated as 0.693/terminal elimination rate constant.","dispersionType":"Standard Deviation","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"MEAN","populationDescription":"All patients in phase 2 who received at least one full or partial dose of PDR001 and had a valid measure of the endpoint.","reportingStatus":"POSTED","timeFrame":"pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).","title":"Phase 2: Terminal Elimination Half-life (T1/2) of PDR001","type":"SECONDARY","unitOfMeasure":"days"}